Oppenheimer says TransMedics short report allegations not supported by checks

Investment Analysis Clubs Saul’s Investing Discussions
1

Surprise, Surprise. Tmdx is not a mafia organization as alleged by the short report. I loaded up under $60. All of the recent flight data looks good, up 5.4% MoM. CEO already confirmed a large beat for Q4. I’m hoping for an initial FY25 raise to 30% during the earnings call. Average MedTech stock is trading at 7x NTM revs with 10-15% growth expected this year. TMDX is currently trading at 4.5 NTM revenue.

Oppenheimer notes that a short report published on January 10 alleged TransMedics (TMDX) to be an operation “engaged in fraudulent billing, extortion, and organ-trafficking,” so over the past three weeks the firm has conducted numerous calls with surgeons and industry contacts. The firm’s checks did not find evidence supporting key allegations in the short report, says the analyst, who has an Outperform rating and $125 price target on the shares.

Oppenheimer says TransMedics short report allegations not supported by checks | Markets Insider

24 Likes
2

I haven’t seen this anywhere Jeff, could you point me to it? I checked the Sec.gov and their investor relations page and couldn’t find it.

1 Like
3

It was at a recent investor conference. An analyst said their numbers suggested something like a $10M beat if I remember correctly. The CEO confirmed.

That news is already out there. Next year’s guide is probably the bigger catalyst. I’d assume there’s some wiggle room in there to give the new CFO a cushion, but we’ll see.

13 Likes
4

Stocknovice is correct. CEO confirmed in the Q & A that they were in the ballbark to beat Q4 by $10M.

43rd Annual J.P. Morgan Healthcare Conference | TransMedics

14 Likes